Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the September 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:SRPT), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Reddit Inc (Symbol: RDDT), where a total volume of 36,071 contracts has been ...

CAMBRIDGE, Mass. -- (BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2025 financial results after ...

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.

CAMBRIDGE, Mass. -- (BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p ...

SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny July 22, 2025 — 09:33 am EDT Written by Zacks Equity Research for Zacks -> ...

(RTTNews) - Sarepta Therapeutics, Inc. (SRPT), Friday acknowledged the Committee for Medicinal Products for Human Use's negative opinion on the conditional marketing authorization for ELEVIDYS in ...

SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.

Sarepta Therapeutics (SRPT) is down more than -9% after an evaluation committee of the European Medicines Agency recommended against the approval of the company’s gene therapy Elevidys.

Sarepta Therapeutics (SRPT) is down more than -5% after an evaluation committee of the European Medicines Agency recommended against the approval of the company’s gene therapy Elevidys.